调研速递|乐心医疗接受众多投资者调研，聚焦业绩与新品要点

Core Viewpoint - The company held an online investor meeting on September 19, 2025, to discuss performance and new products, indicating a proactive approach to investor relations [1][2]. Performance and Strategy - In Q2 2025, the company's net profit attributable to shareholders was 19.35 million, a decrease from 22.94 million in Q1 2025, attributed to external macroeconomic factors such as U.S. tariffs [3]. - The company aims to achieve a net profit target of 80 million for the year through market expansion, product optimization, cost reduction, and detailed management strategies [3]. New Product Highlights - The upcoming smart ring will feature standard monitoring functions like blood oxygen, sleep, and heart rate, along with cardiovascular monitoring capabilities [4]. - The sales strategy includes leveraging the company's brand in the domestic market and focusing on large clients and remote patient monitoring (RPM) in international markets [4]. Cardiovascular AI Model Progress - The cardiovascular AI model is a key component of the company's health management services, utilizing wearable devices to collect physiological data for real-time analysis and intervention [5]. Stock Price and Operational Status - The company reassured that its operations are normal despite stock price fluctuations, which are influenced by multiple factors [6]. - In the first half of 2025, the company reported a net profit of 42.29 million, a year-on-year increase of 21.35%, and has implemented a semi-annual dividend [6]. Management Changes - Recent management adjustments are aimed at aligning with the latest strategic goals, with key personnel bringing valuable experience to enhance operational efficiency [7][8]. Market Value Aspirations - The management is focused on creating long-term value for shareholders and aims to enhance its position as a leading provider of medical monitoring devices, although specific plans for achieving a market value of 100 billion have not been disclosed [9].